Bright Minds Biosciences Inc (NASDAQ:DRUG) shares are trading higher again after soaring last week. The company on Monday ...

Bright Minds Biosciences is working with Firefly Neuroscience, an AI healthcare company, to provide a full analysis of the electroencephalogram data in Bright Minds' Phase 2 clinical trial evaluating ...

Bright Minds Biosciences (TSE:DRUG) has released an update. Bright Minds Biosciences is teaming up again with Firefly Neuroscience to analyze ...

Bright Minds Biosciences (DRUG) announced that it is once again collaborating with Firefly Neuroscience (AIFF), an Artificial Intelligence ...

Firefly Neuroscience partners with Bright Minds Biosciences to analyze positive Phase 1 data of BMB-101 using advanced AI ...

Alpha Cognition Inc. ("Alpha Cognition" or the "Company"), a biopharmaceutical company committed to developing novel ...

In this free webinar, learn how the intended use, technological characteristics and risk classification of a medical device relates to standards. Attendees will gain insights into the intrinsic ...

Its leading candidate, BMB-101, targets serotonin receptors (5-HT2C) to influence brain functions, with promising potential in epilepsy. Bright Minds is also working on BMB-202 to address ...

Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for ...

BMB-201, a selective 5-HT2A/2C receptor agonist, was designed to harness the analgesic potential of serotonin modulation ...

Bright Minds Biosciences (NASDAQ: DRUG), a little-known biotech company, became the talk of the market yesterday after its ...

Bright Minds Biosciences will present scientific posters about various programs in development, including BMB-101, BMB-201 and BMB-202 Bright Minds Biosciences will participate in BIO Europe ...